Back to search
FDAFDA · Food and drugs·Recall number Z-0043-2025

NxTAG Respiratory Pathogen Panel +SARS-CoV-2, REF: I056C0468

Published October 16, 2024 · Recall initiated: September 5, 2024

Summary

FDA records medical device Class II recall Z-0043-2025, published October 16, 2024 and initiated September 5, 2024. Recalling firm: Luminex Molecular Diagnostics Inc; Status: Ongoing; Reported quantity: 613; Lot: Lot/Expiration: IK056C-0033/ 9/30/2024, IK056C-0034/ 10/31/2024, IK056C-0035/ 10/31/2024, IK056C-0036/ 12/31/2024, IK056C-0037/ 12/31/2024, IK056C-0038/ 12/31/2024, IK056C-0039/ 1/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Respiratory pathogen panel may report an elevated rate (7.6% predicted probability of occurrence) of non-specific hMPV target (human Metapneumovirus) results, risk identified predominantly in clinical samples that present positivity for another target, leading to an erroneous co-infection result, can potentially result in hMPV false positives.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Luminex Molecular Diagnostics Inc
Distributor
U Nationwide distribution in the states of OH, CA, NC, WI, TN, TX, MI, NY, MO, FL, MA, NJ, PA, VA, AZ, IL, OK, CO, MN.
Lot
Lot/Expiration: IK056C-0033/ 9/30/2024, IK056C-0034/ 10/31/2024, IK056C-0035/ 10/31/2024, IK056C-0036/ 12/31/2024, IK056C-0037/ 12/31/2024, IK056C-0038/ 12/31/2024, IK056C-0039/ 1/31/2025
Risk classification
Class II
Area (FDA)
device
Country
Canada

Related recalls

Questions about this recall

Was NxTAG Respiratory Pathogen Panel +SARS-CoV-2, REF: I056C0468 recalled?

Yes. FDA published recall Z-0043-2025 on October 16, 2024. Reported hazard: Respiratory pathogen panel may report an elevated rate (7.6% predicted probability of occurrence) of non-specific hMPV target (human Metapneumovirus) results, risk identified predominantly in clinical samples that present positivity for another target, leading to an erroneous co-infection result, can potentially result in hMPV false positives.

What should I do if I have this product?

Voluntary: Firm initiated · Letter